The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers.

ABSTRACT: The development of disease modifying strategies in Parkinson's disease (PD) largely depends on the ability to identify suitable populations after accurate diagnostic work-up. Therefore, patient molecular profiling and disease subtyping are mandatory. Thus far, in clinical trials, PD has been considered to be a "single entity". Conversely, in front of the common feature of nigro-striatal degeneration, PD is pathogenically heterogeneous with a series of several biological and molecular pathways that differently contribute to clinical development and progression. Currently available diagnostic criteria for PD mainly rely on clinical features and imaging biomarkers, thus missing to identify the contribution of pathophysiological pathways, also failing to catch abnormalities occurring in the ea

SUBMITTER: Paolini Paoletti F 

PROVIDER: S-EPMC7072459 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature